OncoSec Medical Inc. Presents Positive Immune Response Data from Phase II Study at the 8th World Congress of Melanoma

Published: Jul 22, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced interim immune response data from the company’s Phase II study of ImmunoPulse in patients with metastatic melanoma. Findings showed that OncoSec’s ImmunoPulse demonstrated a significant change in tumor immunity following treatment with DNA IL-12 and electroporation.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news